Travere Therapeutics (TVTX) Operating Leases (2019 - 2026)

Travere Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• Quarterly Operating Leases fell 54.54% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (down 54.54% YoY) and the FY2025 annual result came in at $11.1 million, down 35.23% from the prior year.
• Operating Leases was $9.6 million for Q1 2026 at Travere Therapeutics, down from $11.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $33.5 million in Q2 2022 and bottomed at $9.6 million in Q1 2026.
• A 5-year average of $23.2 million and a median of $23.9 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases advanced 1.34% — and 2026, when it sank 54.54%.
• Travere Therapeutics' Operating Leases stood at $27.5 million in 2022, then retreated by 17.8% to $22.6 million in 2023, then decreased by 23.97% to $17.2 million in 2024, then plunged by 35.23% to $11.1 million in 2025, then declined by 14.08% to $9.6 million in 2026.
• Business Quant data shows TVTX's Operating Leases at $9.6 million in Q1 2026, $11.1 million in Q4 2025, and $18.4 million in Q3 2025.